These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 23203823)

  • 41. Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.
    Aharoni R; Schlegel PG; Teitelbaum D; Roikhel-Karpov O; Chen Y; Arnon R; Sela M; Chao NJ
    Immunol Lett; 1997 Jul; 58(2):79-87. PubMed ID: 9271317
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation.
    Roback JD; Hossain MS; Lezhava L; Gorechlad JW; Alexander SA; Jaye DL; Mittelstaedt S; Talib S; Hearst JE; Hillyer CD; Waller EK
    J Immunol; 2003 Dec; 171(11):6023-31. PubMed ID: 14634114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers.
    Schlegel PG; Vaysburd M; Chen Y; Butcher EC; Chao NJ
    J Immunol; 1995 Oct; 155(8):3856-65. PubMed ID: 7561092
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
    Fowler DH; Gress RE
    Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of deoxyspergualin on graft-versus-host disease and graft- versus-leukemia in mice.
    Weiss L; Reich S; Slavin S
    Bone Marrow Transplant; 1996 May; 17(5):789-92. PubMed ID: 8733699
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vitro-generated MDSCs prevent murine GVHD by inducing type 2 T cells without disabling antitumor cytotoxicity.
    Messmann JJ; Reisser T; Leithäuser F; Lutz MB; Debatin KM; Strauss G
    Blood; 2015 Aug; 126(9):1138-48. PubMed ID: 26185131
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Depletion of naïve lymphocytes with fas ligand ex vivo prevents graft-versus-host disease without impairing T cell support of engraftment or graft-versus-tumor activity.
    Askenasy N; Mizrahi K; Ash S; Askenasy EM; Yaniv I; Stein J
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):185-95. PubMed ID: 23078782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease.
    Gao L; Yang TH; Tourdot S; Sadovnikova E; Hasserjian R; Stauss HJ
    Blood; 1999 Nov; 94(9):2999-3006. PubMed ID: 10556182
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cytotoxic Pathways in Allogeneic Hematopoietic Cell Transplantation.
    Du W; Cao X
    Front Immunol; 2018; 9():2979. PubMed ID: 30631325
    [TBL] [Abstract][Full Text] [Related]  

  • 50. IL-2-targeted therapy ameliorates the severity of graft-versus-host disease: ex vivo selective depletion of host-reactive T cells and in vivo therapy.
    Yarkoni S; Prigozhina TB; Slavin S; Askenasy N
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):523-35. PubMed ID: 22227590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice.
    Sudres M; Norol F; Trenado A; Grégoire S; Charlotte F; Levacher B; Lataillade JJ; Bourin P; Holy X; Vernant JP; Klatzmann D; Cohen JL
    J Immunol; 2006 Jun; 176(12):7761-7. PubMed ID: 16751424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1).
    Rosen D; Li JH; Keidar S; Markon I; Orda R; Berke G
    J Immunol; 2000 Mar; 164(6):3229-35. PubMed ID: 10706715
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lymphopenia-induced proliferation of donor T cells reduces their capacity for causing acute graft-versus-host disease.
    Maeda Y; Tawara I; Teshima T; Liu C; Hashimoto D; Matsuoka K; Tanimoto M; Reddy P
    Exp Hematol; 2007 Feb; 35(2):274-86. PubMed ID: 17258076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. S1PR5 regulates NK cell responses in preventing graft-versus-host disease while preserving graft-versus-tumour activity in a murine allogeneic haematopoietic stem cell transplantation model.
    Wang F; Zhao S; Gu Z; Zhao X; Yang N; Guan L; Liu T; Wang L; Fang S; Zhu C; Luo L; Li M; Wang L; Gao C
    Hematol Oncol; 2020 Feb; 38(1):89-102. PubMed ID: 31465552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease.
    Yoshida Y; Hirano T; Son G; Iimuro Y; Imado T; Iwasaki T; Fujimoto J
    Am J Physiol Gastrointest Liver Physiol; 2007 Dec; 293(6):G1114-23. PubMed ID: 17761834
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
    Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
    J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation.
    Cooke KR; Gerbitz A; Crawford JM; Teshima T; Hill GR; Tesolin A; Rossignol DP; Ferrara JL
    J Clin Invest; 2001 Jun; 107(12):1581-9. PubMed ID: 11413166
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation.
    Wang XN; Taylor PR; Skinner R; Jackson GH; Proctor SJ; Hedley D; Dickinson AM
    Transplantation; 2000 Aug; 70(3):488-93. PubMed ID: 10949192
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An epithelial target site in experimental graft-versus-host disease and cytokine-mediated cytotoxicity is defined by cytokeratin 15 expression.
    Whitaker-Menezes D; Jones SC; Friedman TM; Korngold R; Murphy GF
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):559-70. PubMed ID: 14506658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.